Executive Summary
Across the 16 filings for the BSE Pharma constituent stream (all dated 2026-11-05), the dominant theme is strong underlying operating momentum tempered by reporting noise from one-offs and prior-year base effects.
Ipca Laboratories posted consolidated revenue up 14% YoY to ₹2,909.94 Cr and PAT up 33% YoY to ₹375.13 Cr, with standalone EBITDA margin expanding to 26.61% from 25.46%, while Abbott India grew revenue 11.0% YoY to ₹1,951.01 Cr and profit 9.2% YoY to ₹453.45 Cr. Glenmark is the key divergence: reported Q2 FY27 consolidated revenue fell 29.8% YoY to Rs. 42,473 million, but the company cites roughly 20% like-for-like growth and ~31% core North America growth once the prior-year ISB 2001 out-licensing income is excluded, so reported figures understate the underlying trend. Dr. Reddy's secured Brazilian ANVISA approval for generic semaglutide, a meaningful incremental-market catalyst in a ~USD 244.6 million segment. Several filings (Sun Pharma, Zydus, GSK, IPCA call audio, Abbott board outcome) are procedural intimations with little quantitative content, and Torrent's ₹3.12 Cr GST penalty is immaterial. Overall the stream reads as constructive for earnings quality, with the main caveats being margin pressure from opex growth at Abbott and Glenmark's concentration of revenue in a volatile North America franchise.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Corporate governance
Tracking the trend? Catch up on the prior BSE Pharma Sector Regulatory Filings digest from November 04, 2026.
Investment Signals (10)
- IPCA Laboratories ↓ (BULLISH)▲
Consolidated revenue +14% YoY to ₹2,909.94 Cr, PAT +33% YoY to ₹375.13 Cr; H1 FY27 PAT +51% to ₹777.02 Cr; standalone EBITDA margin up to 26.61% from 25.46%; institutional formulations exports +45% and generics exports +36% offset a 7% API export decline
- Abbott India ↓ (BULLISH)▲
Q2 revenue +11.0% YoY to ₹1,951.01 Cr and profit +9.2% to ₹453.45 Cr; H1 profit +12.9% to ₹881.97 Cr; EPS ₹213.39 vs ₹195.42 a year earlier
- Dr. Reddy's Laboratories ↓ (BULLISH)▲
ANVISA marketing authorization for generic semaglutide in Brazil (2 mg/1.5 mL and 4 mg/3 mL pens) targeting a ~USD 244.6 million market with partner Aché; Brazil has 16.6 million adults with diabetes
- Glenmark Pharmaceuticals ↓ (BULLISH)▲
Underlying North America core growth ~31% YoY ex-ISB 2001 deferred out-licensing (~25% in H1 FY27); consolidated revenue +5.7% QoQ to Rs. 42,473 million; reported adjusted PAT margin 11.4% and EBITDA margin 20.3%
- Glenmark Pharmaceuticals ↓ (BULLISH)▲
Standalone Q2 PAT of ₹434.89 Cr versus a ₹739.19 Cr loss a year earlier, with standalone exceptional items shrinking to ₹1,429.25 million from ₹9,317.94 million
- Glenmark Pharmaceuticals ↓ (BEARISH)▲
Diabetes franchise value growth -4.2% in JUL-SEP'26 with market share slipping from 1.2% to 1.0%, while the IPM grew 17.7%; Europe was the slowest region at 6.2% YoY
- Glenmark Pharmaceuticals ↓ (BEARISH)▲
Consolidated PAT of ₹263.83 Cr fell about 57% from ₹610.35 Cr a year earlier and standalone PAT fell ~41% sequentially from ₹735.64 Cr, indicating earnings volatility
- Abbott India ↓ (BEARISH)▲
Other expenses +21.2% YoY to ₹192.85 Cr and employee costs +13.4% to ₹180.40 Cr, both outpacing revenue growth of 11.0%; other income fell to ₹68.06 Cr from ₹69.95 Cr
- Mankind Pharma ↓ (BULLISH)▲
Independent SES ESG Research assigned an ESG rating of 64.8 for FY26 without company engagement, a third-party validation signal
- Sun Pharmaceutical ↓ (BULLISH)▲
Participating in three investor conferences on 17–18 November 2026 in Mumbai with no UPSI to be disclosed, offering a near-term management access event without new guidance
Risk Flags (8)
- ▼
Consolidated Q2 FY27 revenue fell 29.8% YoY to Rs. 42,473 million from Rs. 60,469 million, with North America down 72.9% to Rs. 12,089 million due to the high prior-year out-licensing base
- Glenmark Pharmaceuticals/Legal Settlement↓ [MEDIUM RISK]▼
$15.28 million settlement with Humana in US generic drug price-fixing litigation; the company denies all allegations, but the filing signals ongoing exposure in the US generics pricing matter
- ▼
Reported PAT of Rs. 2,638 million (6.2% margin) versus adjusted PAT of Rs. 4,852 million (11.4% margin), a wide gap that reduces earnings visibility
- Glenmark Pharmaceuticals/Franchise Erosion↓ [MEDIUM RISK]▼
Diabetes franchise declined 4.2% in value with share slipping to 1.0%, indicating competitive pressure in a core therapy area
- Abbott India/Opex Growth↓ [MEDIUM RISK]▼
Other expenses (+21.2%) and employee costs (+13.4%) grew well ahead of revenue (+11.0%), a margin-dilution signal if sustained into subsequent quarters
- Torrent Pharmaceuticals/Tax Contingency↓ [LOW RISK]▼
GST penalty of ₹3,12,32,860 under Section 74 for FY 2020–21 to FY 2023–24 relating to pre-acquisition JB Chemicals; management expects no material impact but intends to appeal
- IPCA Laboratories/Subsidiary Claims↓ [LOW RISK]▼
₹24.26 Cr provision for claims at subsidiary Niche Generics plus API export decline of 7% YoY to ₹298.65 Cr and other income down 10%
- Glenmark Pharmaceuticals/Europe Growth↓ [LOW RISK]▼
Europe grew only 6.2% YoY in Q2 FY27, the slowest of the major regions, limiting diversification benefit
Opportunities (7)
- Dr. Reddy's Laboratories/Semaglutide Brazil Launch↓ (OPPORTUNITY)◆
ANVISA approval opens a ~USD 244.6 million market with Aché as partner; launch timing and pricing will be the next catalysts to monitor
- Glenmark Pharmaceuticals/Normalised Earnings Power↓ (OPPORTUNITY)◆
Adjusted PAT margin of 11.4% and ~31% core North America growth suggest the reported decline understates the business; a re-rating is possible if the market adopts the underlying view
- IPCA Laboratories/Pending Amalgamation↓ (OPPORTUNITY)◆
Proposed amalgamation of Krebs Biochemicals & Industries Ltd. could simplify group structure and consolidate earnings; margin expansion (consolidated EBITDA 22.97% vs 21.68%) supports the story
- IPCA Laboratories/Export Mix Shift↓ (OPPORTUNITY)◆
Institutional formulations exports +45% and generics +36% indicate a shift away from API dependence, a durable structural positive for margin quality
- Abbott India/Consistent Compounder↓ (OPPORTUNITY)◆
Six-month profit +12.9% and EPS growth of ~9% with stable other income and a Walker Chandiok limited review suggest steady, low-volatility earnings for defensive exposure
- IPCA Laboratories/Finance Cost Relief↓ (OPPORTUNITY)◆
Standalone finance costs fell 59% YoY to ₹4.68 Cr, a structural benefit to bottom-line conversion if debt levels stay low
- Sun Pharmaceutical/Investor Access↓ (OPPORTUNITY)◆
Three institutional forums on 17–18 November 2026 give an avenue to probe management on US specialty and India growth trajectory ahead of year-end
Sector Themes (6)
- Base Effects Distort Reported Growth◆
Glenmark's reported consolidated revenue (-29.8% YoY) versus ~20% like-for-like growth shows prior-year one-off licensing income inflating comparisons; investors should adjust for out-licensing and exceptional items across the sector when reading headline numbers
- Profit Growth Outpacing Revenue at Leading Indian Pharma◆
IPCA (PAT +33% vs revenue +14%) and Abbott (PAT +9.2% vs revenue +11%, with opex growing faster than sales) show profitability trends diverging, with IPCA benefiting from margin expansion and Abbott facing cost pressure
- Export and Regulated-Market Diversification◆
IPCA's institutional and generics exports growing 36–45% and Dr. Reddy's entry into Brazil's semaglutide market point to geographic and product diversification as a key growth lever for Indian pharma beyond the US
- GLP-1 and Diabetes Competition Intensifying◆
Dr. Reddy's Brazil semaglutide approval alongside Glenmark's diabetes franchise share loss (1.2% to 1.0%) indicates rising generic competition in the incretin/diabetes space, compressing share for incumbents
- Governance and Disclosure Hygiene Remains High◆
Multiple filings reflect routine Regulation 30 compliance (investor meet schedules with UPSI disclaimers, conference call recordings, ESG ratings, Board outcome filings), reflecting an orderly disclosure environment across BSE Pharma constituents
- Exceptional Items and Legal Overhang in US Generics◆
Glenmark's $15.28 million Humana settlement in generic drug price-fixing litigation and its large standalone exceptional items indicate continued legal and one-off charges as a recurring feature of US generic exposure
Watch List (8)
-
Monitor how North America reported revenue trends once the ISB 2001 out-licensing base drops out, with H2 FY27 reporting as the test; investor presentation filed 05-Nov-2026
-
Watch launch timing, pricing, and early share capture with Aché following ANVISA approval (announced 05-Nov-2026)
-
CITIC-Securities-CLSA 29th India Forum (17-Nov-2026) and Avendus Spark INDX plus JM Financial India Conference (18-Nov-2026) in Mumbai; watch for commentary on US specialty and India growth
-
Avendus Spark Investor Conference on 17-Nov-2026 and JM Financial India Xchange 2026 on 18-Nov-2026 in Mumbai, both routine, but management commentary may offer guidance color
-
Dr. Amrut Naik appointed CEO effective 11-Nov-2026 with 26+ years of experience; watch for strategic priorities and any portfolio or capital allocation changes in early tenure
-
Monitor appeal filing against the ₹3.12 Cr penalty (orders dated 03–04 Nov 2026) for any escalation beyond the company's expectation of no material impact
-
Track finalisation of the $15.28 million Humana settlement and any related US generic price-fixing litigation developments
-
Monitor progress of the proposed amalgamation of Krebs Biochemicals & Industries Ltd. and subsidiary Niche Generics claim resolution (₹24.26 Cr provision)
Filing Analyses
(16)
05-11-2026
GlaxoSmithKline Pharmaceuticals Limited filed a disclosure under Regulation 30 of SEBI LODR Regulations, 2015, informing stock exchanges about the upload of a video recording of its Analyst/Institutional Investor Meeting. The filing provides no financial data, performance metrics, or specific business updates.
05-11-2026
Mankind Pharma Limited has disclosed that SES ESG Research Private Limited, a SEBI-registered ESG Rating Provider, has independently assigned the Company an ESG Rating of 64.8 for FY26 based on publicly available information. The Company did not engage SES for this rating, and the disclosure has been made under Regulation 30 & 51 of the SEBI LODR Regulations.
- · The ESG rating of 64.8 was independently assigned by SES, not commissioned by the Company.
- · The rating is based on publicly available information for FY26.
- · The disclosure is made voluntarily under Regulation 30 & 51 of the SEBI LODR Regulations.
05-11-2026
Ipca Laboratories reported Q2 FY27 consolidated revenue from operations of ₹2909.94 Cr, up 14% YoY from ₹2556.50 Cr, with consolidated PAT of ₹375.13 Cr up 33% YoY. However, growth was uneven: API exports declined 7% YoY to ₹298.65 Cr and other income fell 10% YoY to ₹25.03 Cr, while institutional formulations exports surged 45% and generics exports rose 36%. For H1 FY27, consolidated revenue rose 17% to ₹5698.04 Cr and PAT jumped 51% to ₹777.02 Cr, though other income declined 17% YoY.
05-11-2026
Ipca Laboratories reported strong Q2 FY27 standalone revenue growth of 17% YoY to ₹2,255.61 Cr and net profit growth of 27% YoY to ₹387.29 Cr. Consolidated net profit surged 33% YoY to ₹375.13 Cr. However, other income declined 14% standalone and 10% consolidated, while API exports fell 7% YoY. The company is pursuing an amalgamation of Krebs Biochemicals & Industries Ltd. and recorded exceptional items including a ₹24.26 Cr provision for claims at its subsidiary Niche Generics.
- · Standalone EBITDA margin improved to 26.61% in Q2 FY27 from 25.46% in Q2 FY26.
- · Consolidated EBITDA margin improved to 22.97% in Q2 FY27 from 21.68% in Q2 FY26.
- · Standalone finance costs declined 59% YoY to ₹4.68 Cr in Q2 FY27.
- · Consolidated finance costs declined 36% YoY to ₹12.57 Cr in Q2 FY27.
- · Standalone tax expense increased 41% YoY to ₹146.42 Cr in Q2 FY27.
- · Consolidated tax expense increased 44% YoY to ₹155.63 Cr in Q2 FY27.
- · Domestic formulations income grew 14% YoY to ₹1,157.20 Cr in Q2 FY27.
- · Institutional exports grew 45% YoY to ₹115.76 Cr in Q2 FY27.
- · Generics exports grew 36% YoY to ₹364.48 Cr in Q2 FY27.
- · API domestic sales grew 56% YoY to ₹135.56 Cr in Q2 FY27.
- · Total standalone assets stood at ₹10,423.02 Cr as of Sept 30, 2026, up from ₹9,775.50 Cr as of Mar 31, 2026.
- · Total consolidated assets stood at ₹13,132.93 Cr as of Sept 30, 2026, up from ₹12,370.19 Cr as of Mar 31, 2026.
- · Standalone net worth was ₹7,979.35 Cr as of Sept 30, 2026.
- · Consolidated net worth was ₹8,063.81 Cr as of Sept 30, 2026.
- · The company has only one operating segment: Pharmaceuticals.
- · The amalgamation of Krebs Biochemicals & Industries Ltd. is pending consents/approvals with an appointed date of April 1, 2026.
05-11-2026
Sun Pharmaceutical Industries Limited has intimated under Regulation 30 of SEBI LODR the schedule of three upcoming analyst/institutional investor meetings on 17 and 18 November 2026, including the CITIC-Securities-CLSA 29th India Forum, the Avendus Spark INDX Annual Investor Conference, and the JM Financial Annual India Conference 2026, all in Mumbai in physical and group/one-on-one formats. The company stated it will not disclose any Unpublished Price Sensitive Information (UPSI) at these meetings and that the schedule is subject to change.
- · Meetings scheduled for 17-Nov-26 (CITIC-Securities-CLSA 29th India Forum) and 18-Nov-26 (Avendus Spark INDX and JM Financial Annual India Conference 2026)
- · All three meetings are in Mumbai, held in physical format, with both group and one-on-one components
- · No UPSI to be disclosed at these meetings; schedule subject to change due to exigencies on either side
05-11-2026
Alkem Laboratories Limited has appointed Dr. Amrut Naik as Chief Executive Officer and Key Managerial Personnel, effective 11 November 2026, based on the recommendation of the Nomination and Remuneration Committee and the Board's decision at its 03 November 2026 meeting. This revised Regulation 30 disclosure was filed to add the Board meeting's commencement (12:20 p.m.) and conclusion (1:25 p.m.) times at BSE's request. The filing contains no quantitative financial data.
- · Dr. Amrut Naik holds a Ph.D. (Tech) in Pharmacology, a Master's in Pharmaceutical Science and a Bachelor's in Pharmaceutical Science, and has 26+ years of experience across Branded Formulations, Generics, APIs, Biologics, Vaccines, Specialty and Innovation-led portfolios.
- · Term of appointment runs for the duration of his employment with the Company; no relationships with other directors are disclosed.
- · The filing references SEBI Master Circular HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026.
05-11-2026
Glenmark Pharmaceuticals reported unaudited results for the quarter and half year ended 30 September 2026, approved by the Board on 5 November 2026. Standalone Q2 FY27 total revenue from operations was ₹2,475.82 Cr (million figures converted: ₹24,758.20 million), up about 61% from ₹1,538.66 Cr in the year-ago quarter, while standalone PAT was ₹434.89 Cr, a sharp swing from a loss of ₹739.19 Cr a year earlier. However, sequentially standalone PAT fell about 41% from ₹735.64 Cr in Q1, and consolidated PAT of ₹263.83 Cr declined about 57% from ₹610.35 Cr in the year-ago quarter.
- · Standalone exceptional items were a ₹1,429.25 million loss in Q2 FY27 versus a ₹9,317.94 million loss in Q2 FY26, and consolidated exceptional items were ₹2,838.75 million in Q2 FY27 versus ₹2,838.75 million in the same period (no change), reflecting lower one-off charges on a standalone basis.
- · Consolidated net sales declined to ₹41,570.91 million in Q2 FY27 from ₹60,037.94 million in Q2 FY26, while standalone net sales rose to ₹23,753.73 million from ₹12,195.32 million.
- · Standalone employee benefits expense rose to ₹4,497.66 million in Q2 FY27 from ₹4,536.75 million in the prior-year quarter, a slight decline.
- · Consolidated finance costs were ₹637.67 million in Q2 FY27 versus ₹664.63 million in Q2 FY26, a modest decrease.
- · Standalone other equity stood at ₹2,41,221.04 million as at 31/03/2026 and ₹2,52,107.89 million as at 30/09/2026; consolidated cash and cash equivalents rose to ₹12,899.29 million from ₹11,747.09 million at 31/03/2026, while consolidated operating cash flow was negative ₹2,033.18 million for H1 FY27 versus positive ₹28,355.67 million in H1 FY26.
- · Consolidated other income fell sharply to ₹25.41 million in Q2 FY27 from ₹2,006.29 million in Q2 FY26, a material drag on total income.
05-11-2026
Glenmark Pharmaceuticals reported Q2 FY27 consolidated revenue of Rs. 42,473 million, down 29.8% YoY from Rs. 60,469 million, as the prior-year quarter was inflated by large North America out-licensing income; on a like-for-like basis, consolidated revenue grew approximately 20% YoY. Adjusted PAT was Rs. 4,852 million (11.4% margin) versus reported PAT of Rs. 2,638 million (6.2% margin), and EBITDA was Rs. 8,638 million (20.3% margin). The filing also discloses a $15.28 million settlement with Humana in the US generic drug price-fixing litigation, though the company states it denies all allegations.
- · North America reported revenue fell 72.9% YoY because Q2 FY26 included a large one-time out-licensing income base; the 31% core growth figure is the underlying trend.
- · Glenmark's Diabetes franchise declined 4.2% in value growth (JUL-SEP'26) while the IPM grew 17.7%, and its market share slipped from 1.2% to 1.0%.
- · Europe was the slowest-growing major region at 6.2% YoY in Q2 FY27.
- · Reported PAT of Rs. 2,638 million is roughly 46% below adjusted PAT of Rs. 4,852 million, indicating material adjustments between the two measures.
- · The Humana settlement of $15.28 million has been fully provided for in the company's financials, so no further P&L hit is expected from it.
- · Glenmark's Q2 India formulations growth (16.7%) outpaced the IPM (13.8%) per IQVIA secondary sales data.
05-11-2026
Glenmark Pharmaceuticals filed its Q2 FY27 Investor Presentation under Regulation 30 on November 05, 2026. Consolidated revenue for Q2 FY27 was Rs. 42,473 million, down 29.8% YoY on a reported basis (from Rs. 60,469 million), but up 5.7% QoQ from Rs. 40,185 million, and the company cites ~20% like-for-like YoY growth. The sharp reported decline is driven by North America, which fell 72.9% YoY to Rs. 12,089 million; the company attributes this to a high prior-year base and notes that core North America growth was ~31% excluding deferred out-licensing income from ISB 2001.
- · North America core business growth excluding ISB 2001 deferred out-licensing income was ~31% YoY in Q2 FY27 (~25% in H1 FY27)
- · Q2 FY27 consolidated revenue fell 29.8% YoY on reported basis, driven largely by the high prior-year North America base
- · Q2 FY27 Adjusted PAT margin was 11.4% and EBITDA margin was 20.3%
- · India revenue declined 7.3% QoQ from Rs. 14,321 Mn in Q1 FY27 to Rs. 13,274 Mn in Q2 FY27
- · Europe growth moderated to 6.2% YoY in Q2 FY27 and 8.9% in H1 FY27, described as uneven due to market conditions
- · Trastuzumab Rezetecan first commercial launch anticipated during H2 FY27; first regulatory approval in Australia received for enrolment initiation
- · IGI intends to submit an IND for ISB 2301 by end of CY26; ISB 2001 updated Phase 1 data accepted for oral presentation at ASH 2026
- · BioCryst returns full licensing rights to STAR-0310 (ISB 830-X8) to IGI effective November 4, 2026; IGI evaluating strategic pathways including partnership
- · Almirall expects Phase II HS study readout for LAD191 in 2027
- · Company expects 10 market launches of RYALTRIS® in upcoming quarters and additional Monroe-based launches
05-11-2026
IPCA Laboratories Limited has filed an audio link under Regulation 30 of SEBI LODR for its Q2FY27 earnings and business update conference call held on November 5, 2026 from 16:00 hrs IST. The filing is a disclosure of the call recording and transcript location rather than a disclosure of financial results, so no specific financial figures, growth rates, or performance metrics are contained in the filing itself.
- · Conference call covered Q2FY27 earnings and business update
- · Call held Thursday, November 5, 2026 from 16:00 to hrs IST
- · Audio recording and transcripts are available on the company's website under shareholders information / conference calls section
- · Filed under Regulation 30 of SEBI (LODR) Regulations, 2015
- · BSE Scrip Code 524494; NSE Symbol IPCALAB
05-11-2026
Torrent Pharmaceuticals disclosed under Regulation 30 that the Commercial Tax Officer of State Tax, Tiruvallur, Tamil Nadu, passed orders dated 03 and 04 November 2026 under Section 74 of the GST Act, 2017, imposing a penalty of ₹ 3,12,32,860 for FY 2020-21 to FY 2023-24. The demand relates to GST matters of JB Chemicals and Pharmaceuticals Limited, pre-acquisition. The company plans to appeal and states it does not reasonably expect any material financial impact.
- · Penalty relates to GST matters of JB Chemicals for FY 2020-21 to FY 2023-24, a period prior to Torrent's acquisition of JB Chemicals
- · Order was received on 04 November 2026 at 06:10 pm
- · Authority: Commercial Tax Officer of State Tax, Tiruvallur, Tamil Nadu
05-11-2026
Zydus Lifesciences Limited has informed the stock exchanges (BSE and NSE) that it will participate in JM Financial's 17th Annual Flagship Conference, 'India Xchange 2026', in Mumbai on November 18, 2026. The disclosure is a routine investor-relations notice and contains no financial results, guidance, or quantitative performance data.
05-11-2026
Abbott India Limited's Board approved the unaudited financial results for the quarter and half year ended September 30, 2026, with a Limited Review Report from Walker Chandiok & Co. LLP, the Statutory Auditors. The filing is a Regulation 30 Board Meeting outcome and attaches the results statement, but the statement's line-item figures are not reproduced in the body text provided, so no specific revenue, profit, or EPS amounts can be extracted from this content.
- · Board meeting commenced at 4.00 pm and concluded at 6.30 pm on November 5, 2026
- · Results were approved under Regulation 33 of the SEBI Listing Regulations; scrip code 500488 on BSE
- · The full Statement of Financial Results is enclosed separately and is not reproduced in the provided content
05-11-2026
Abbott India Limited reported unaudited results for the quarter ended September 30, 2026, with revenue from operations of ₹1,951.01 Cr, up from ₹1,757.15 Cr in the corresponding quarter of the prior year (+11.0% YoY). Profit for the period rose to ₹453.45 Cr from ₹415.27 Cr (+9.2% YoY), while basic/diluted EPS was ₹213.39 for the quarter versus ₹195.42 a year earlier. Growth was healthy overall, but the year-on-year rise in other expenses (+21.2%) and employee benefits (+13.4%) outpaced the top-line growth, and other income declined slightly to ₹68.06 Cr from ₹69.95 Cr.
- · Six-month revenue from operations rose to ₹3,764.69 Cr from ₹3,495.50 Cr (+7.7% YoY), and six-month profit for the period rose to ₹881.97 Cr from ₹781.13 Cr (+12.9% YoY).
- · Other expenses grew 21.2% YoY to ₹192.85 Cr in the quarter, and employee benefits expense grew 13.4% YoY to ₹180.40 Cr, both outpacing revenue growth.
- · Other income declined to ₹68.06 Cr from ₹69.95 Cr in the year-ago quarter, a 2.7% decrease.
- · Finance costs fell to ₹5.95 Cr from ₹7.55 Cr in the year-ago quarter, a 21.2% decrease.
05-11-2026
Zydus Lifesciences Limited has informed the stock exchanges (BSE and NSE) that it will participate in the Avendus Spark Investor Conference in Mumbai on November 17, 2026. The filing is a routine intimation issued by the Company Secretary and Compliance Officer to keep members and investors informed; it contains no financial results, guidance, or quantitative performance data.
05-11-2026
Dr. Reddy's Laboratories announced that Brazil's ANVISA has granted marketing authorization for its generic semaglutide injection, used for treating type 2 diabetes mellitus. This approval expands Dr. Reddy's semaglutide presence into Brazil, a key Latin American market with an estimated semaglutide market of approximately USD 244.6 million. The company plans to launch the product in Brazil with partner Aché.
- · The product will be available as a pre-filled, multi-dose injectable pen in two presentations: 2 mg/1.5 mL and 4 mg/3 mL, for once-weekly dosing.
- · Brazil has 16.6 million adults aged 20–79 living with diabetes and ranks sixth globally in terms of the number of adults living with diabetes.
- · The approval builds on Dr. Reddy's broader semaglutide strategy.
- · Dr. Reddy's plans to launch semaglutide in Brazil with Aché.
Get daily alerts with 10 investment signals, 8 risk alerts, 7 opportunities and full AI analysis of all 16 filings
₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: BSE Pharma Sector Regulatory Filings
🇮🇳 More from India
View all →November 06, 2026
India Pre-Market Regulatory Roundup — November 06, 2026
India Pre-Market Regulatory Roundup
November 06, 2026
India Quarterly Results BSE NSE Announcements — November 06, 2026
India Quarterly Results BSE NSE Announcements
November 06, 2026
India Upcoming Corporate Actions BSE NSE — November 06, 2026
India Upcoming Corporate Actions BSE NSE
November 06, 2026
India RBI Monetary Policy Repo Rate Decisions — November 06, 2026
India RBI Monetary Policy Repo Rate Decisions